Amgen Names Yuji Orihara President, Amgen KK
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 1, 2006--Amgen
(NASDAQ:AMGN), today announced the appointment of Yuji Orihara to the
position of president and representative director, Amgen KK, effective
immediately. Amgen KK was formed in 1992 in Japan as a wholly owned
subsidiary of Amgen Inc. Orihara will be responsible for all aspects
of Amgen's commercial efforts in Japan and will be based at the Amgen
KK headquarters in Tokyo.
Amgen is building Amgen KK to become a full commercial operation
and a robust and growing clinical research operation. Over the next
several years, Amgen's commercial operations in Japan are expected to
expand significantly as the company prepares for the potential launch
of its late-stage pipeline products. Japan is a priority market for
Amgen and the company expects to increase its current staff of
approximately 120 in Japan to more than 300 by 2009.
"Yuji's significant experience in Japan's pharmaceutical industry
make him exceptionally qualified to meet the challenges of achieving
our goal of bringing Amgen's vital medicines to patients in Japan,"
said George Morrow, executive vice president, Global Commercial
Operations. "I am confident that he will prove a strong leader and a
collaborative partner within Amgen's global operations to ensure
Orihara joins Amgen KK from Novartis Pharma K.K. where he most
recently served as senior managing director in charge of the Oncology,
Transplantation/Immunology/Infectious Diseases, and Ophthalmic
Business Units, with responsibility for a sales force of 400 people
and generating $500 million in sales. In addition, Orihara also led
Business Development and Licensing as well as Market Access and Public
Policy for Novartis Japan. Prior to Novartis, Orihara was the
president of UCB Japan where he was successful in building a
significant sales force and commercializing a series of products that
yielded revenues in excess of $300 million.
Orihara received his undergraduate degree in Chemical and Applied
Physics Engineering from Keio University in Tokyo and his master's
degree in Business Administration from New York University.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe,
effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR'S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
Anne McNickle, 805-447-5890 (media)
Mary Klem, 805-447-6979 (media)
Arvind Sood, 805-447-1060 (investors)